The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Featured:
During the EHA 2022 Congress, the Lymphoma Hub spoke with Marek Trněný, Charles University, Prague, CZ. We asked, Is peripheral neuropathy in patients with diffuse large B-cell lymphoma (DLBCL) more severe after pola-R-CHP vs R-CHOP treatment?
Is peripheral neuropathy in patients with DLBCL more severe after pola-R-CHP vs R-CHOP treatment?
Trněný begins by outlining the POLARIX study, which showed significant improvement in progression-free survival (PFS) for patients treated with pola-R-CHP vs R-CHOP. Trněný highlights findings on the toxicity profile, and underlines the need for increased research into the effect that peripheral neuropathy has on quality of life. Also, Trněný discusses the findings of his study, including incidence and duration of peripheral neuropathy in both treatment arms.